| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | RECRUITING | PHASE1 | 2023-01-24 | 2027-04 | 2027-04 |
| NCT05377996 | A Study of XMT-1660 in Participants With Solid Tumors | RECRUITING | PHASE1 | 2022-08-15 | 2027-05 | 2026-12 |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) | TERMINATED | PHASE3 | 2022-06-23 | 2023-09-29 | 2023-09-29 |
| NCT04907968 | Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer | TERMINATED | PHASE1 | 2021-06-11 | 2023-10-03 | 2023-10-03 |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b | TERMINATED | PHASE1 | 2020-05-11 | 2022-09-30 | 2022-09-30 |
| NCT06517485 | First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b | COMPLETED | PHASE1 | 2019-07-30 | 2022-08-03 | 2022-05-31 |
| NCT06517433 | First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b | COMPLETED | PHASE1 | 2017-12-12 | 2021-07-09 | 2021-07-09 |
| NCT03319628 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2017-12-12 | 2024-10-31 | 2023-05-31 |
| NCT02952729 | Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 | COMPLETED | PHASE1 | 2016-11-21 | 2019-01-28 | 2019-01-28 |
| NCT00455052 | A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2011-03 | 2011-12 | 2011-12 |
| NCT01011972 | A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2010-03 | 2013-09 | 2013-09 |